source
- Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellersEli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.
- HHS adopts enforcement discretion allowing compounding pharmacies to produce six unapproved peptidesHHS announced an "enforcement discretion" policy that permits compounding pharmacies to make six peptide products that have not received FDA approval. The list includes BPC-157 and TB-500, which a…